Results 31 to 40 of about 383,968 (297)

Arterial dysgenesis and limb defects : Clinical and experimental examples [PDF]

, 2017
Acknowledgements This article is dedicated to Dr David S. Packard Jr. With thanks to Dr John DeSesso, Dr Lewis B. Holmes, Dr Mark Levinsohn, Dr David S.
Hootnick, David R., Vargesson, Neil
core   +1 more source

Clinical Features and Outcomes Differ between Skeletal and Extraskeletal Osteosarcoma. [PDF]

, 2014
Background. Extraskeletal osteosarcoma (ESOS) is a rare subtype of osteosarcoma. We investigated patient characteristics, overall survival, and prognostic factors in ESOS. Methods.
Boscardin, W John, DuBois, Steven G, Goldsby, Robert, Matthay, Katherine K, Thampi, Sheila   +4 more
core   +2 more sources

Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study

Bone Reports
Background: Patients with bone metastases from solid tumors often have additional treatment with bone targeted agents (BTAs) to avoid symptomatic skeletal events (SSEs) such as clinically significant pathological fracture leading toradiation therapy or ...
Michael Mark, Alfonso Rojas Mora, Thomas Winder, Anastasios Stathis, Andreas Jakob, Gisela Müller, Stefanie Hayoz, Patrick Reimann, Ulf Petrausch, Roger von Moos   +9 more
doaj   +1 more source

Spontaneous physical activity down-regulates Pax7 in cancer cachexia [PDF]

, 2015
Emerging evidence suggests that the muscle microenvironment plays a prominent role in cancer cachexia. We recently showed that NF-kB - induced Pax7 overexpression impairs the myogenic potential of muscle precursors in cachectic mice, suggesting that ...
Adamo, Sergio, Annibali, Daniela, Aulino, Paola, Barteri, Fabio, Berardi, Emanuele, Coletti, Dario, Moresi, Viviana, Pigna, Eva   +7 more
core   +5 more sources

Optimizing skeletal‐related events prevention in patients with advanced prostate cancer [PDF]

Asia-Pacific Journal of Clinical Oncology, 2020
AbstractIn patients with metastatic castration‐resistant prostate cancer (mCRPC), bone is a dominant site of metastasis. Bone metastases often lead to skeletal‐related events (SREs), which include pain, spinal cord compression and fractures. The treatment of bone metastases in men with mCRPC aims to improve SRE‐free survival, quality of life and ...
openaire   +2 more sources

Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients [PDF]

Value in Health, 2018
To evaluate the economic burden of treating skeletal-related events (SREs) in prostate cancer (PC) patients with bone metastasis from an insurer perspective.We conducted a retrospective cohort analysis using claims data. PC patients with bone metastasis were identified in the MarketScan Databases between January 1, 2004, and March 1, 2014.
Yue, Zhong, Adriana, Valderrama, Jianying, Yao, Prina, Donga, Pinar, Bilir, Peter J, Neumann   +5 more
openaire   +2 more sources

Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials

Frontiers in Oncology, 2023
Denosumab, a fully humanized monoclonal neutralizing antibody, inhibits activation of the RANK/RANKL/OPG signaling pathway through competitive binding with RANKL, thereby inhibiting osteoclast-mediated bone resorption.
Junjie Lu, Desheng Hu, Yan Zhang, Chen Ma, Lin Shen, Bo Shuai   +5 more
doaj   +1 more source

Outcomes of Live Virus Vaccination in Patients With Vascular Anomalies Being Treated With Sirolimus

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Live vaccination in patients with vascular anomalies (VA) receiving sirolimus remains controversial due to immunosuppressive effects and theoretical risks. Procedure This single‐center retrospective study included patients with VA less than 4 years old at the start of sirolimus therapy who were incompletely vaccinated.
Svatava Merkle, Kiersten Ricci, Kelly Blache, Rebecca A. Marsh, Adrienne M. Hammill, Elissa Engel   +5 more
wiley   +1 more source

The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study

BMC Cancer
Background Daratumumab (Dara), a humanized IgGκ monoclonal antibody targeting CD38, has shown significant efficacy in the treatment of multiple myeloma (MM).
Xinrong Li, Hua Wang, Yizhen Li, Jing Zhou, Nianhui Yang, Xiaolei Wei, Xiangran Cai, Zeyu Xiao, Juan Du, Hui Zeng   +9 more
doaj   +1 more source

Managing Bone Metastases with Denosumab: Real-World Data and Critical Monitoring Points in Breast, Lung, and Prostate Cancers

Medicina
Background and Objectives: Advanced solid organ tumors, particularly breast, lung, and prostate cancers, frequently metastasize to bone, leading to debilitating skeletal-related events (SREs).
Sibel Oyucu Orhan, Bedrettin Orhan, Şeyma Esenbuğa, Seda Sali, Burcu Caner, Birol Ocak, Ahmet Bilgehan Şahin, Adem Deligönül, Türkkan Evrensel, Erdem Çubukçu   +9 more
doaj   +1 more source